IS8049A - Lyfjablanda sem felur í sér 5-metýl-2-(2'-klór-6'-flúoranilínó)fenýlediksýru - Google Patents

Lyfjablanda sem felur í sér 5-metýl-2-(2'-klór-6'-flúoranilínó)fenýlediksýru

Info

Publication number
IS8049A
IS8049A IS8049A IS8049A IS8049A IS 8049 A IS8049 A IS 8049A IS 8049 A IS8049 A IS 8049A IS 8049 A IS8049 A IS 8049A IS 8049 A IS8049 A IS 8049A
Authority
IS
Iceland
Prior art keywords
fluoroanilino
chloro
methyl
pharmaceutical composition
phenylacetic acid
Prior art date
Application number
IS8049A
Other languages
English (en)
Other versions
IS2658B (is
Inventor
Forenzo Patrick
Y. Khaled Maha
Wang Barbara
Lawrence Zielinski Joseph
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32990870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS8049(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IS8049A publication Critical patent/IS8049A/is
Publication of IS2658B publication Critical patent/IS2658B/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
IS8049A 2003-03-12 2005-09-28 Lyfjablanda sem felur í sér 5-metýl-2-(2'-klór-6'-flúoranilínó)fenýlediksýru IS2658B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45414503P 2003-03-12 2003-03-12
PCT/EP2004/002528 WO2004080451A1 (en) 2003-03-12 2004-03-11 Pharmaceutical composition comprising 5-methyl-2-2’-(chloro-6’-fluoroanilino) phe nylacetic acid

Publications (2)

Publication Number Publication Date
IS8049A true IS8049A (is) 2005-09-28
IS2658B IS2658B (is) 2010-08-15

Family

ID=32990870

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8049A IS2658B (is) 2003-03-12 2005-09-28 Lyfjablanda sem felur í sér 5-metýl-2-(2'-klór-6'-flúoranilínó)fenýlediksýru

Country Status (29)

Country Link
US (2) US20060094787A1 (is)
EP (1) EP1603550B1 (is)
JP (1) JP4580921B2 (is)
KR (1) KR20050109077A (is)
CN (1) CN100345536C (is)
AR (1) AR043536A1 (is)
AT (1) ATE418332T1 (is)
AU (1) AU2004218921B2 (is)
BR (1) BRPI0408270A (is)
CA (1) CA2518393A1 (is)
CL (1) CL2004000496A1 (is)
DE (1) DE602004018622D1 (is)
EC (1) ECSP055998A (is)
ES (1) ES2318277T3 (is)
HR (1) HRP20050787A2 (is)
IL (1) IL170518A (is)
IS (1) IS2658B (is)
MA (1) MA27670A1 (is)
MX (1) MXPA05009686A (is)
MY (1) MY139455A (is)
NO (1) NO20054662L (is)
NZ (1) NZ542218A (is)
PE (1) PE20041063A1 (is)
PT (1) PT1603550E (is)
RU (1) RU2363462C2 (is)
TN (1) TNSN05222A1 (is)
TW (1) TWI327913B (is)
WO (1) WO2004080451A1 (is)
ZA (1) ZA200506750B (is)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1673079A1 (en) * 2003-10-08 2006-06-28 Novartis AG Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid
KR100900915B1 (ko) * 2007-05-07 2009-06-05 이연제약주식회사 메게스트롤 아세테이트를 함유하는 현탁액 제제 및 이의제조방법
WO2009064681A2 (en) * 2007-11-12 2009-05-22 Novartis Ag Liquid compositions comprising valsartan
EP2926810A1 (en) * 2014-03-31 2015-10-07 Sanovel Ilac Sanayi ve Ticaret A.S. Oral liquid pharmaceutical formulations of loxoprofen
US11207307B2 (en) * 2016-06-16 2021-12-28 Azurity Pharmaceuticals, Inc. Composition and method for proton pump inhibitor suspension
EP3509592A4 (en) 2016-09-09 2020-07-22 Cutispharma, Inc. SUSPENSIONS AND DILUENTS FOR METRONIDAZOLE AND BACLOFEN
US11433074B2 (en) 2017-06-22 2022-09-06 Triact Therapeutics, Inc. Methods of treating glioblastoma
EP3687501A4 (en) 2017-09-29 2021-06-23 Triact Therapeutics, Inc. INIPARIB FORMULATIONS AND THEIR USES
US10751333B1 (en) 2019-07-16 2020-08-25 Cutispharma, Inc. Compositions and kits for omeprazole suspension
US11633478B2 (en) 2019-07-16 2023-04-25 Azurity Pharmaceuticals, Inc. Compositions and kits for Omeprazole suspension

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112604A (en) * 1989-09-01 1992-05-12 Riker Laboratories, Inc. Oral suspension formulation
US5840768A (en) * 1997-06-04 1998-11-24 Fmc Corporation MCC: alginate pharmaceutical suspensions
US6103260A (en) * 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US20020028794A1 (en) * 2000-07-21 2002-03-07 Brubaker Greg Allen Megestrol acetate suspension
AR030630A1 (es) * 2000-09-11 2003-08-27 Novartis Ag Composiciones farmaceuticas
CN1638760A (zh) * 2002-01-07 2005-07-13 法马西亚公司 用环加氧酶-2选择性抑制剂和阿司匹林的组合治疗疼痛、炎症和炎症相关疾病
CA2480832A1 (en) * 2002-04-05 2003-10-23 Nitromed, Inc. Nitric oxide donors, compositions and methods of use

Also Published As

Publication number Publication date
HK1086492A1 (en) 2006-09-22
NO20054662L (no) 2005-12-05
JP2006519811A (ja) 2006-08-31
NZ542218A (en) 2009-01-31
CA2518393A1 (en) 2004-09-23
HRP20050787A2 (en) 2006-12-31
BRPI0408270A (pt) 2006-03-07
RU2363462C2 (ru) 2009-08-10
AR043536A1 (es) 2005-08-03
CL2004000496A1 (es) 2005-01-14
AU2004218921A1 (en) 2004-09-23
US20090048344A1 (en) 2009-02-19
EP1603550B1 (en) 2008-12-24
IS2658B (is) 2010-08-15
TWI327913B (en) 2010-08-01
MXPA05009686A (es) 2005-10-20
PT1603550E (pt) 2009-03-20
KR20050109077A (ko) 2005-11-17
EP1603550A1 (en) 2005-12-14
AU2004218921B2 (en) 2007-05-17
ZA200506750B (en) 2007-02-28
ATE418332T1 (de) 2009-01-15
TW200505429A (en) 2005-02-16
RU2005131310A (ru) 2006-05-10
US20060094787A1 (en) 2006-05-04
MA27670A1 (fr) 2005-12-01
ECSP055998A (es) 2006-01-27
PE20041063A1 (es) 2005-03-07
WO2004080451A1 (en) 2004-09-23
CN100345536C (zh) 2007-10-31
NO20054662D0 (no) 2005-10-11
TNSN05222A1 (en) 2007-06-11
IL170518A (en) 2010-11-30
CN1756541A (zh) 2006-04-05
ES2318277T3 (es) 2009-05-01
JP4580921B2 (ja) 2010-11-17
MY139455A (en) 2009-10-30
DE602004018622D1 (de) 2009-02-05

Similar Documents

Publication Publication Date Title
IS8353A (is) Lyfjablanda sem felur í sér lantanefnasambönd
IS8460A (is) Lyfjafræðileg samsetning sem inniheldur kvetíapín
EP2007362A4 (en) ORAL PHARMACEUTICAL FORMS USING A THROMBOZYTE HEMMER AND ACID HEMMER
GB0012850D0 (en) Cyclic amino acid derivatives useful as pharmaceutical agents
EP1648421A4 (en) ORAL SOLUBLE FILMS
ATE427296T1 (de) Phenoxyessigsaurederivate
EE200000497A (et) Kiiresti lahustuv peroraalne ravimvorm
DK1467724T3 (da) Farmaceutisk sammensætning med agomelatin til dispergering i mundhulen
FR2901478B1 (fr) Forme pharmaceutique orale multimicroparticulaire a liberation prolongee
FI20022129A7 (fi) Rasvahappokoostumus, sen valmistus ja käyttö
IS2658B (is) Lyfjablanda sem felur í sér 5-metýl-2-(2'-klór-6'-flúoranilínó)fenýlediksýru
ITMI20042477A1 (it) Uso di antibiotici a strutura dichetoditiopiperazinica per la preparazione di composizioni farmaceutiche antiangiogeniche
ATE345817T1 (de) Feste lösung einer schwerwasserlöslichen substanz zur oralen verabreichung
IS2616B (is) Lyfjablanda sem felur í sér levóþýroxínnatríum
EP2098237A4 (en) ANALGETIC AGENT WITH A CYCLIC PHOSPHATIDINE ACID DERIVATIVE
DK1638418T3 (da) Aminosyretilsætning til et sundt mikrobiota-økosystem
IS7303A (is) 3-fenýl-2-arýlalkýlþíóprópíónsýruafleiður sem valvís gerandefni PPAR-ALFA
PL1784174T3 (pl) Kompozycja farmaceutyczna zawierająca gabapentynę
ITMI20062254A1 (it) Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
IS7581A (is) Lyfjasamsetning
DE502004003170D1 (de) Schmelzformulierte, multipartikuläre orale darreichungsform enthaltend clavulansäure
ATE429227T1 (de) Pharmazeutische zusammensetzung für die orale verabreichung eines pyrazol-3-carbonsäurederivats
EP1566181A4 (en) NEW MEDICAMENT TO REDUCE NEW TRANSMISSION FLUCTUATIONS
FR2869902B1 (fr) Composition, notamment cosmetique, comprenant un ester de ((dialkylamino)alcoxy) ethanol
EE200300378A (et) Farmatseutiline kompositsioon